July 14, 2022 News by Lindsey Shapiro, PhD Yoga Course Found to Ease Fatigue, Anxiety in MS Patients in Study A six-week program combining yoga and group discussions about resilience led to significant reductions in fatigue and anxiety, and improvements in well-being, for people with multiple sclerosis (MS), according to results from a pilot study. Researchers noted that the program, known asĀ LoveYourBrain Yoga, “may improve a range of…
July 11, 2022 News by Lindsey Shapiro, PhD Sepsis in MS Is Linked to Longer Hospital Stays, Higher Costs Sepsis, a life-threatening response to an infection that can result in tissue damage and organ failure, was reported in nearly one-third of multiple sclerosis (MS) patients admitted to an intensive care unit (ICU), a Texas study found. This condition was linked to longer hospital stays, higher costs, and a…
July 8, 2022 News by Lindsey Shapiro, PhD Early RRMS Treatment Lessens Need for Disability Pension in Denmark Delaying the start of disease-modifying therapies (DMTs) increases the risk of people with relapsing-remitting multiple sclerosis (RRMS) needing a disability pension to compensate for a permanent reduced capacity to work,Ā Ā according to a Danish study. The study, āTime to first treatment and risk of disability pension…
July 7, 2022 News by Lindsey Shapiro, PhD Smoking Linked to Worse Outcomes in RRMS Patients After 10 Years Smoking is associated with lower brain volume, more brain lesions, and greater disability and attention deficits among people with relapsing-remitting multiple sclerosis (RRMS) after 10 years,Ā according to a study in Norway. “The findings imply that patients should be advised and offered aid in smoking cessation shortly after diagnosis, to…
July 6, 2022 News by Lindsey Shapiro, PhD Income, Education Levels Linked to Fatigue in MS Patients in New Study Lower levels of income and education, as well as other socioeconomic factors, are associated with the presence and severity of fatigue among people with multiple sclerosis (MS), a new study in Norway found. Women, smokers, and those with other co-existing conditions or a higher disability level also were more…
July 5, 2022 News by Lindsey Shapiro, PhD Assistive Device Makes It Easier to Self-administer Nabiximols: Study An assistive device made it significantly easier and more comfortable for multiple sclerosis (MS) patients with arm and hand mobility problems to self-administer nabiximols ā an oral spray containing compounds found in the cannabis plant ā a study found. Trained nurses involved in the study agreed with its…
July 1, 2022 News by Lindsey Shapiro, PhD Phase 3 Tolebrutinib Trials Pause US Enrollment Over Safety Concerns The U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on Phase 3 trials testing the investigational therapy tolebrutinib in people with multiple sclerosis (MS) and myasthenia gravis based on reports of medication-induced liver injury. Under the clinical hold, new enrollment at U.S. sites…
June 30, 2022 News by Lindsey Shapiro, PhD UK Study: Fatigue Often Influences Quality of Life in MS Fatigue is a common symptom among people living with multiple sclerosis (MS), and has a significant negative impact on physical and psychological function, as well as quality of life, a U.K. study reported. Citing the study as the “largest study on fatigue in MS from U.K.,” Ā researchers emphasized that…
June 29, 2022 News by Lindsey Shapiro, PhD Nabiximols Fails to Meet Trial Goal of Easing Leg Spasticity The Phase 3 RELEASE MSS1 clinical trial testing nabiximols oral spray failed to meet its primary goal of easing leg spasticity in patients with multiple sclerosis (MS), according to Jazz Pharmaceuticals, the company currently developing the nabiximols clinical program. Enrolling 68 MS patients,…
June 29, 2022 News by Lindsey Shapiro, PhD OM1 Develops Algorithm to Estimate EDSS Scores OM1 has created an artificial intelligence (AI)-based algorithm to estimate scores on the expanded disability status scale (EDSS), an established method for evaluating disability and disease progression in people with multiple sclerosis (MS). The algorithm, using a method called machine learning, was trained to estimate EDSS scores…
June 28, 2022 News by Lindsey Shapiro, PhD Ublituximab’s Therapeutic Benefit Revealed in ULTIMATE Trials Analyses Ublituximab, anĀ investigational antibody-based treatment for multiple sclerosis (MS), was efficacious across most patient subgroups, and led to marked improvements in disability and quality of life over nearly two years. This is according to new exploratory analyses from the identical Phase 3 ULTIMATE I and II trials, which evaluated…
June 27, 2022 News by Lindsey Shapiro, PhD Alcohol Use, Cholesterol Tied to Liver Injury With Pulse Steroid Therapy A short course of high-dose methylprednisoloneĀ was associated with signs of mild liver injury in nearly 3% of multiple sclerosis patients given this treatment, according to a study in Iran. Notably, a history of alcohol abuseĀ and hyperlipidemia ā higher-than-normal blood levels of fatty molecules such as cholesterol ā were…
June 23, 2022 News by Lindsey Shapiro, PhD aHSCT, Stem Cell Therapy for RRMS, Troubled by Unknowns, Paper Says Autologous hematopoietic stem cell transplant (aHSCT) has shown some promise as a treatment option for highly active relapsing-remitting multiple sclerosis (RRMS), but more clinical evidence is needed to support its use, a team of researchers in the U.K. suggest. “Uncertainty remains as to how aHSCT compares with current…
June 22, 2022 News by Lindsey Shapiro, PhD Erectile Dysfunction Can Affect Most Men With MS, Analysis Suggests The risk of erectile dysfunction was about three times greater in men with multiple sclerosis (MS) compared with healthy men, according to a recent meta-analysis of published studies. It was identified in nearly half of the 2,760 adult male patients in these studies, highlighting the importance of diagnosing…
June 22, 2022 News by Lindsey Shapiro, PhD MS Bike, Canadian Society’s Annual Fundraiser, Returns to Live Rides The Multiple Sclerosis Society of CanadaĀ has openedĀ MS Bike, an annual cycling event to raise awareness and funds for research and services that make the difference for the more than 90,000 Canadians living with multiple sclerosis (MS). Conducted in an entirely virtual format due to COVID-19 in 2020…
June 21, 2022 News by Lindsey Shapiro, PhD Beer Consumption May Be Linked to MS Risk: Meta-analysis Alcohol intake is not significantly associated with an increased risk of developing multiple sclerosis (MS), but specifically drinking beer may elevate the risk, according to a recent meta-analysis. The association, however, was limited by a small number of included studies. “Further large-scale prospective studies should be conducted to verify…
June 20, 2022 News by Lindsey Shapiro, PhD Bioasis Purchases EGF Therapy Platform for MS, Other Diseases Cresence AS has sold its epidermal growth factor (EGF) platform comprising investigational therapies for multiple sclerosis (MS) and other neurodegenerative diseases to Bioasis Technologies. Under the terms of the agreement, Bioasis will own all intellectual property related to the EGF platform. In exchange, it will issue…
June 15, 2022 News by Lindsey Shapiro, PhD Ekso’s Wearable Exoskeleton Cleared by FDA for Walking Rehab Use The U.S. Food and Drug Administration has given Ekso Bionics clearance to market its wearable robotic exoskeleton to aid in rehabilitation programs to improve gait and mobility in people with multiple sclerosis (MS). Dubbed EksoNR, the device had been approved by the regulatory agency for stroke and spinal…
June 10, 2022 News by Lindsey Shapiro, PhD Evusheld Boosts Antibodies Against COVID-19 in Vaccinated Patients Treatment with Evusheld (tixagevimab co-packaged with cilgavimab) after COVID-19 vaccination significantly boosted the levels of antibodies against the virus among people with multiple sclerosis (MS) who were taking B-cell targeted therapies, a small study showed. “This is important as it provides a different strategy for protection against…
June 8, 2022 News by Lindsey Shapiro, PhD Blocking Kidney Protein Prevents Progression in MS Mouse Model A protein called nephronectin mediates autoimmunity in a mouse model of multiple sclerosis (MS), and blocking this protein was found to prevent disease progression and processes that drive T-cells toward an inflammatory state, researchers reported. Study findings support nephronectin, a protein involved in kidney development, as a promising treatment…
June 7, 2022 News by Lindsey Shapiro, PhD Blood Test to Monitor MS Activity Supports Optimal Care, Octave Says A blood biomarker test developed by Octave can effectively monitor overall disease activity in people with multiple sclerosis (MS), helping to improve the care being given, the company reported. The assay, dubbed the MS Disease Activity (MSDA) test, can also be used to monitor disease activity across…
June 6, 2022 News by Lindsey Shapiro, PhD Fibroblast Cell Therapy Shows Early Promise in MS Patients A single infusion of FibroBiologics‘ investigational cell therapy, CYMS101, was able to inhibit disease activity in a mouse model of multiple sclerosis (MS), and appeared safe in early MS clinical trials, the company announced in a press release. Data from the mouse and human studies were…
May 31, 2022 News by Lindsey Shapiro, PhD $3.9M Grant Awarded to Study Effects of Low-glycemic Diet The U.S. Department of Defense (DOD) has awarded $3.9 million to fund clinical research to test the impact of a low-glycemic diet on physical, cognitive, and psychological function in people with multiple sclerosis (MS). The four-year project, called “Impact of diet quality and calorie restriction on physical function and…
May 27, 2022 News by Lindsey Shapiro, PhD Fecal Transplants Show Safety, Potential to Enrich Gut in Small Trial Repeated fecal transplants from healthy donors were safe and well-tolerated in a small group of people with relapsing-remitting multiple sclerosis (RRMS), a study reported. Treatment also showed a potential to ease intestinal permeability in MS and enrich the presence of protective microbes in the gut. Given that the trial…
May 25, 2022 News by Lindsey Shapiro, PhD Exergaming Shows ‘Superior’ Efficacy at Easing MS Symptoms in Trial A five-week, high-intensity video game-based exercise program called exergaming outperformed other forms of exercise at easing symptoms and improving life quality in people with multiple sclerosis (MS), a small trial found. While all exercise programs slowed symptom worsening over two subsequent years of lower-intensity exercises, exergaming led to the…
May 23, 2022 News by Lindsey Shapiro, PhD Consistency in DMT Use ‘Low’ in US, Influenced by Side Effects, Insurance Persistent use of a single disease-modifying therapy (DMT) over a three-year period was low among people with relapsing forms of multiple sclerosis (MS), a U.S. study found. DMT discontinuations or switches were initiated in some cases by prescribers, specialty pharmacists, or patients for reasons that included treatment side…
May 20, 2022 News by Lindsey Shapiro, PhD Genetic Indicators of High BMI in Childhood Linked to Higher MS Risk Genetic variants that contribute to a high body mass index (BMI) during childhood are associated withĀ an increased risk of developing multiple sclerosis (MS), a study found. The relationship is likely influenced by the fact that a higher BMI in childhood is linked to obesity in adulthood and a ālonger…
May 19, 2022 News by Lindsey Shapiro, PhD Low-impact Aquatic Exercise a Good Alternative, but Access Is a Barrier Aquatic exercise is used less often by people with multiple sclerosis (MS) than land-based exercise, but it’s generally well liked by those who use it, a patient survey found. A lack of pool access and associated expenses remain significant barriers to aquatic exercise. The team also found that exercise…
May 18, 2022 News by Lindsey Shapiro, PhD Gilenya, Tysabri Show Superiority at Preventing Relapses in Children Gilenya (fingolimod) and Tysabri (natalizumab) were more effective at lowering relapse rates in children with multiple sclerosis (MS) than interferon-beta, according to a recent meta-analysis. Findings like these can be leveraged for better clinical trial design, the researchers wrote. If used to determine “historical” relapse rates that…
May 13, 2022 News by Lindsey Shapiro, PhD NervGen Cleared to Enroll Final Group in Trial of NVG-291 NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an investigational treatment for multiple sclerosis (MS) and other nervous system diseases. A safety review committee cleared the…